BioSpace News Archive

Amicus Therapeutics announced positive interim results from its CLN6 Batten disease gene therapy program. Batten disease is a fatal neurologic illness that results in children losing the ability to walk, speak, think and see.

Rakuten Medical was formerly called Aspyrian Therapeutics. Since launching in 2015, it has raised almost $500 million.

The test developed at Washington University, which is likely years away from clinical use, tests for amyloid in the blood—if the blood amyloid levels are very low, it’s possible that the individual may have amyloid plaques in the brain.

South San Francisco-based RAPT Therapeutics announced it is postponing its initial public offering (IPO) it filed earlier to raise $86 million via selling 5 million shares at $14 to $16 per share. No reasons were given for the postponement.

An experimental vaccine for respiratory syncytial virus (RSV) showed positive results in a Phase I clinical trial. Researchers from The University of Texas at Austin and others reported that a single dose of the vaccine produced significant evidence of RSV-neutralizing antibodies that were sustained for several months.

Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.

Pharma and biotech companies from across the globe expand their leadership teams and boards.

Accelerate Diagnostics, Inc. announced the release and CE marking of its latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices.

Transgene announces that the independent Data Monitoring Committee of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis.

Exact Sciences Corp. announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.